7,586.41

+6.34

+0.08%

52,194.72

+424.41

+0.82%

25,396.76

-40.24

-0.16%

2,821.83

+9.98

+0.36%

4.8920

-0.0370

-0.75%

20.04

+0.62

+3.19%

3,962.60

+63.70

+1.63%

76,856.57

-828.77

-1.07%

Crude Oil Dec 26

96.22

-7.90

-7.59%

US Private Equity

10,850.63

-82.20

-0.75%

Iceland - Delayed Quote ISK

Alvotech (ALVO.IC)

566.00 -9.00 (-1.57%)

At close: 3:22:58 PM GMT

Loading Chart for ALVO.IC

Chart Range Bar

Interval:

In partnership with ChartIQ

Alvotech to Present at Upcoming Investor Conferences in November

Alvotech to Present at Upcoming Investor Conferences in November

Alvotech to Present at Upcoming Investor Conferences in November

Alvotech to Present at Upcoming Investor Conferences in November

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

Mobilize your Website

View Site in Mobile | Classic

Share by: